
|Videos|February 24, 2023
A Cardiologist’s Perspective on Cardiovascular Risk Assessment in Prostate Cancer
Direct insight from a cardiologist on the advent of cardiovascular risk when treating a patient for prostate cancer.
Advertisement
Episodes in this series

January 2023 AbbVie Inc. Company Confidential
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Focal therapy for prostate cancer frequently used outside guideline-supported groups
2
Real-world data support PSA below 0.2 ng/mL as key response threshold in mCSPC
3
Published LITESPARK-011 data show PFS benefit with belzutifan plus lenvatinib in ccRCC
4
Active surveillance use for low-risk prostate cancer reaches 93% in VA System
5















